Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
Prahlad V. Raninga, Andy Lee, Debottam Sinha, Lan‐Feng Dong, Keshava K. Datta, Xue Lu, Priyakshi Kalita‐de Croft, Mriga Dutt, Michelle M. Hill, Normand Pouliot, Harsha Gowda, Murugan Kalimutho, Jiřı́ Neužil, Kum Kum Khanna
Abstract
: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.
Topics & Concepts
Triple-negative breast cancerCancer researchProteasomeBreast cancerProteasome inhibitorMetastasisIn vivoMedicineLung cancerCancerTargeted therapyCancer cellBiologyInternal medicineBiochemistryBiotechnologyUbiquitin and proteasome pathwaysHistone Deacetylase Inhibitors ResearchCancer-related Molecular Pathways